Your browser doesn't support javascript.
loading
CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu, Yi; Wang, Sanmei; Schubert, Maria-Luisa; Lauk, Annika; Yao, Hao; Blank, Maximilian Felix; Cui, Chunhong; Janssen, Maike; Schmidt, Christina; Göllner, Stefanie; Kleist, Christian; Zhou, Fengbiao; Rahfeld, Jens-Ulrich; Sauer, Tim; Schmitt, Michael; Müller-Tidow, Carsten.
Afiliação
  • Liu Y; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Wang S; Molecular Medicine Partnership Unit (MMPU), European Molecular Biology Laboratory (EMBL) and Heidelberg University Hospital, Heidelberg, Germany.
  • Schubert ML; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Lauk A; Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
  • Yao H; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Blank MF; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Cui C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Janssen M; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Schmidt C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Göllner S; Shanghai University of Medicine and Health Sciences, Shanghai, China.
  • Kleist C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Zhou F; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Rahfeld JU; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Sauer T; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Schmitt M; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Müller-Tidow C; Fraunhofer Institute for Cell Therapy and Immunology IZI, Halle, Germany.
Int J Cancer ; 150(7): 1141-1155, 2022 04 01.
Article em En | MEDLINE | ID: mdl-34766343
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Imunoterapia Adotiva / Transplante de Células-Tronco Hematopoéticas / Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico / Receptores de Antígenos Quiméricos / Gemtuzumab Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Imunoterapia Adotiva / Transplante de Células-Tronco Hematopoéticas / Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico / Receptores de Antígenos Quiméricos / Gemtuzumab Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha